Mechanisms of Osteoporosis after Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 2 A, 2000, Pages 165-174

  Weilbaecher, Katherine N ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow transplantation; Osteoclast; Osteoporosis

Indexed keywords

HORMONE; IMMUNOSUPPRESSIVE AGENT;

BONE REMODELING; DRUG EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; METABOLISM; MULTIMODALITY CANCER THERAPY; OSTEOPOROSIS; PHYSIOLOGY; RADIATION EXPOSURE; REVIEW;

BONE REMODELING; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HORMONES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OSTEOPOROSIS;

EID: 0033654590     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70039-5     Document Type: Article

References (76)

1. Wasnich R. Epidemiology of osteoporosis. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 1999.
2. Casteneda S, Carmona L, Carvajal I, Arranz R, Diaz A, Garcia-Vadillo A. Reduction of bone mass in women after bone marrow transplantation. Calcif Tissue Int. 1997;60:343-347.
3. Eberling P, Thomas D, Erbas B, Hopper J, Szer J, Grigg A. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res. 1999;14:342-350.
4. Baron R. Anatomy and ultrastructure of bone. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 1999.
5. Manolagas S, Weinstein R, Jilka R. Basic principles of bone physiology. In: Body JJ, ed. Tumor Bone Diseases and Osteoporosis in Cancer Patients. Vol. 1. 1st ed. New York: Marcel Dekker; 1999.
6. Lian J, Stein G, Canalis E, Robey P, Boskey A. Bone formation: osteoblast lineage cells, growth factors, matrix proteins, and the mineralization process. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1. Philadelphia: Lippincott Williams and Wilkins; 1999.
7. Joyner C, Bennett A, Triffitt J. Identification and enrichment of human osteoprogenitor cells by using differentiation stage-specific monoclonal antibodies. Bone. 1997;21:1-6.
8. Centrella M, McCarthy T, Canalis E. Transforming growth factor-beta and remodeling of bone. J Bone Joint Surg Am. 1991;73:1418-1428.
9. Mundy G. Bone remodeling. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 1999.
10. Shane E. Transplantation osteoporosis. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 1999.
11. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitor factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95:3597-3602.
12. Lacey D, Timms E, Tan H, Kelley M, Dunstan C, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176.
13. Felix R, Cecchini M, Hofstetter W, Elford P, Stutzer A, Fleisch H. Impairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse. J Bone Miner Res. 1990;5:781-789.
14. Lagasse E, Weissman I. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell. 1997;89:1021-1031.
15. Yakisan E, Schirg E, Zeidler C, Bishop N, Reiter A, Hirt A, et al. High incidence of significant bone loss in patients with severe congenital neutropenia (Kostmann's syndrome). J Pediatr. 1997;131:592-597.
16. Kong Y, Yoshida H, Sarosi I, Tan H, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323.
17. Dougall W, Glaccum M, Charrier K, Rohrbach K, Brasel K, DeSmedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13:2412-2424.
18. Hofbauer L. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur J Endrocrinol. 1999;141:195-210.
19. Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R, Nguyen H, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
20. Wiktor-Jedrzejczak W, Bartocci A, Ferrante A, Ansari A, Sell K, Pollard J, Stanely E. Total absence of colony stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A. 1990;87:4828-4832.
21. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature. 1990;345:442-444.
22. Kitamura H, Kawata H, Takahashi F, Higuchi Y, Furuichi T, Ohkawa H. Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. Am J Pathol. 1995;147:1682-1691.
23. Juppner H, Brown E, Kronenberg H. Parathyroid hormone. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 1999.
24. Holick M. Vitamin D: Photobiology, metabolism, mechanism of action, and clinical applications. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1. Philadelphia: Lippincott Williams and Wilkins; 1999.
25. Lukert B. Glucocorticoid-induced osteoporosis. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 1999.
26. Shane E, Rivas M, McMahon D. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab. 1997;82:1497-1506.
27. Monegal A, Navasa M, Guanabens N. Osteoporosis and bone mineral metabolism in cirrhotic patients referred for liver transplantation. Calcif Tissue Int. 1997;60:148-154.
28. Ferrari S, Nicod L, Hamacher J. Osteoporosis in patients undergoing lung transplantation. Eur Respir J. 1996;9:2378-2382.
29. Rodino M, Shane E. Osteoporosis after organ transplantation. Am J Med. 1998;104:459-469.
30. Bakker B, Massa G, Rijn Av, Mearadji A, Kamp HVd, Niemer-Tucker M, et al. Effects of total-body irradiation on growth, thyroid and pituitary gland in rhesus monkeys. Radiother Oncol. 1999;51:187-192.
31. Achermann J, Hindmarsh P, Brook C. The relationship between the growth hormone and insulin-like growth factor axis in long-term survivors of childhood brain tumours. Clin Endocrinol (Oxf). 1998;49:639-645.
32. Gertner J. Childhood and adolescence. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 1999.
33. Eastell R. Pathogenesis of postmenopausal osteoporosis. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 1999.
34. Francis R. The effects of testosterone on osteoporosis in men. Clin Endocrinol. 1999;50:411-414.
35. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997;15:1341-1347.
36. Kelly P, Atkinson K, Ward R, Sambrook P, Biggs J, Eisman J. Reduced bone mineral density in men and women with allogeneic bone marrow transplantation. Transplantation. 1990;50:811-883.
37. Sanders J. Growth and development after bone marrow transplantation. In: Forman S, Blume K, Thomas E, eds. Bone Marrow Transplantation. Boston: Blackwell Scientific Publications; 1994.
38. Orwoll E. Osteoporosis in men. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 1999.
39. Riggs B, Khosla S, Melton L. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998;13:763-773.
40. Winding B, Jorgensen H, Christiansen C. Osteoporosis in patients with a history of breast cancer: causes and diagnosis. In: Body JJ, ed. Tumor Bone Diseases and Osteoporosis in Cancer Patients. Vol. 1. New York: Marcel Dekker; 1999.
41. Manolagas S, Weinstein R. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res. 1999;14:1061-1066.
42. Frost H. On the estrogen-bone relationship and postmenopausal bone loss: a new model. J Bone Miner Res. 1999;14:1473-1477.
43. Ratcliffe M, Lanham S, Reid D, Dawson A. Bone mineral density (BMD) in patients with lymphoma: the effects of chemotherapy, intermittent corticosteroids and premature menopause. Hematol Oncol. 1992;10:181-187.
44. Lane N, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am. 1998;27:465-483.
45. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents on the skeleton. J Bone Miner Res. 1996;11:1-7.
46. Moreno A, Clemente J, Crespo C, Martinez A, Navarro M, et al. Pelvic insufficiency fractures in patients with pelvic irradiation. Int J Radiat Oncol Bio Phys. 1999;44:61-66.
47. Grigsby P, Roberts H, Perez C. Femoral neck fracture following groin irradiation. Int J Radiat Oncol Bio Phys. 1995;32:63-67.
48. Wall J, Kaste S, Greenwal C, Jenkins J, Douglass E, Pratt C. Fractures in children treated with radiotherapy for soft tissue sarcoma. Orthopedics. 1996;19:657-664.
49. Dalinka M, Mazzeo V. Complications of radiation therapy. Crit Rev Diagn Imaging. 1985;23:235-267.
50. Dyess C, Carter D, Kirchner J, Baron R. A morphometric comparison of the changes in the laryngeal skeleton associated with invasion by tumor and by external-beam radiation. Cancer. 1987;59:1117-1122.
51. Takahashi S, Sugimoto M, Kotoura Y, Sasai K, Oka M, Yamamuro T. Long-term changes in the haversian systems following high-dose irradiation: an ultrastructural and quantitative histomorphological study. J Bone Joint Surg Am. 1994;76:722-738.
52. Sugimoto M, Takahashi S, Kotoura Y, et al. Osteocyte viability after high-dose irradiation in the rabbit. Clin Orthop. 1993;297:247-252.
53. Maeda M, Bryant M, Yamagata M, Li G, Earle J, Chao E. Effects of irradiation on cortical bone and their time-related changes. A biomechanical and histomorphological study. J Bone Joint Surg. 1988;70:392-399.
54. Warner J, Evans W, Webb D, Bell W, Gregory J. Relative osteopenia after treatment for acute lymphoblastic leukemia. Pediatr Res. 1999;45:544-551.
55. Gilsanz V, Carlson M, Roe T, Ortega J. Osteoporosis after cranial irradiation for acute lymphoblastic leukemia. J Pediatr. 1990;117:238-244.
56. Headley J, Theriault R, Blanc AL, Vassilopoulou-Sellin R, Hortobagyi G. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest. 1998;16:6-11.
57. Kother M, Schindler J, Oette K, Berthold F. Abnormalities in serum osteocalcin values in children receiving chemotherapy including ifosfamide. In Vivo. 1992;6:219-221.
58. Rude R. Magnesium depletion and hypermagnesemia. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1 4th ed. Philadelphia: Lippincott Williams and Wilkins; 1999.
59. Shaughnessy S, Hirsh J, Bhandari M, Muir J, Young E, Weitz J. A histomorphometric evaluation of heparin-induced bone loss after discontinuation. Blood. 1999;93:1231-1236.
60. Bhandari M, Hirsh J, Weitz J, Young E, Venner T, Shaughnessy S. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost. 1998;80:413-417.
61. Toubert M, Socie G, Gluckman E, Aractingi S, Esperou H, Devergie A, et al. Short and long-term follow-up of thyroid dysfunction after allogeneic bone marrow transplantation without the use of preparative total body irradiation. Br J Haematol. 1997;98:453-457.
62. Cohen A, Rovelli R, Zecca S, Van-Lint M, Parodi L, Grasso L, Uderzo C. Endocrine late effects in children who underwent bone marrow transplantation: review. Bone Marrow Transplant. 1998;21:S64-S67.
63. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant. 1998;22:873-881.
64. Deeg H. Delayed complications after bone marrow transplantation. In: Forman S, Blume K, Thomas E, eds. Bone Marrow Transplantation. Boston: Blackwell Scientific Publications; 1994.
65. Greenspan S, Greenspan F. The effect of thyroid hormone on skeletal integrity. Ann Intern Med. 1999;130:750-758.
66. Baran D. Secondary causes of osteoporosis: thyrotoxicosis and lack of weight bearing. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 1999.
67. Takahashi T, Wada T, Mori M, Kokai Y, Ishii S. Overexpression of the granulocyte colony-stimulating factor gene leads to osteoporosis in mice. Lab Invest. 1996;74:827-834.
68. Takamatsu Y, Simmons P, Moore R, Morris H, To L, Levesque J. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood. 1998;92:3465-3473.
69. Takahashi N, Udagawa N, Akatsu T, Tanaka H, Shionome M, Suda T. Role of colony-stimulating factors in osteoclast development. J Bone Miner Res. 1991;6:977-985.
70. Goodman W, Coburn J, Slatopolsky E, Salusky I. Renal osteodystrophy in adults and children. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Vol. 1 4th ed. Philadelphia: Lippincott Williams and Wilkins; 1999.
71. Withold W, Wolf H, Kollbach S, Heyll A, Schneider W, Reinauer H. Relationship between bone metabolism and plasma cytokine levels in patients at risk of post-transplantation bone disease. Eur J Clin Chem Clin Biochem. 1996;34:295-299.
72. Yoneda T, Williams P, Myoi A, Michigami T, Mbalaviele G. Cellular and molecular mechanisms of development of skeletal metastases. In: Body JJ, ed. Tumor Bone Diseases and Osteoporosis in Cancer Patients. Vol. 1. New York: Marcel Dekker; 1999.
73. Fleisch H. Bisphosphonates: introduction and mechanisms of action in tumor prevention. In: Body JJ, ed. Tumor Bone Diseases and Osteoporosis in Cancer Patients. Vol. 1. New York: Marcel Dekker; 1999.
74. Rodan G. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol. 1998;38:375-388.
75. Fisher J, Rogers M, Halasy J, Luckman S, Hughes D, Masarachia P, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A. 1999;96:133-138.
76. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946-1949.